Disulfidptosis-Related Classification Patterns and Tumor Microenvironment Characterization in Skin Cutaneous Melanoma

References

• Leclerc J , Ballotti R , Bertolotto C . Pathways from senescence to melanoma: focus on MITF sumoylation. Oncogene 36(48), 6659–6667 (2017).
   PubMed Web of Science ®Google Scholar
• Arnold M , Singh D , Laversanne M et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA dermatology 158(5), 495–503 (2022).
   PubMed Web of Science ®Google Scholar
• Coricovac D , Dehelean C , Moaca EA et al. Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review. Int. J. Mol. Sci. 19(6), (2018).
   Web of Science ®Google Scholar
• Thrane K , Eriksson H , Maaskola J , Hansson J , Lundeberg J . Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma. Cancer Res. 78(20), 5970–5979 (2018).
   PubMed Web of Science ®Google Scholar
• Quintanilla-Dieck MJ , Bichakjian CK . Management of Early-Stage Melanoma. Facial Plast. Surg. Clin. North Am. 27(1), 35–42 (2019).
   PubMed Web of Science ®Google Scholar
• Sung H , Ferlay J , Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Villani A , Potestio L , Fabbrocini G , Troncone G , Malapelle U , Scalvenzi M . The Treatment of Advanced Melanoma: Therapeutic Update. Int. J. Mol. Sci. 23(12), (2022).
   Web of Science ®Google Scholar
• Liu X , Nie L , Zhang Y et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat. Cell Biol. 25(3), 404–414 (2023).
   PubMed Web of Science ®Google Scholar
• Xue W , Qiu K , Dong B et al. Disulfidptosis-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in colon adenocarcinoma. Cancer Cell Int. 23(1), 218 (2023).
   PubMed Web of Science ®Google Scholar
• Li J , Yang C , Zheng Y . A novel disulfidptosis and glycolysis related risk score signature for prediction of prognosis and ICI therapeutic responsiveness in colorectal cancer. Sci. Rep. 13(1), 13344 (2023).
   PubMed Web of Science ®Google Scholar
• Zhao S , Wang L , Ding W et al. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework. Front. Endocrinol. (Lausanne) 14, 1180404 (2023).
   PubMed Web of Science ®Google Scholar
• Peng K , Wang N , Liu Q et al. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma. J. Cancer Res. Clin. Oncol. 149(15), 13793–13810 (2023).
   PubMed Web of Science ®Google Scholar
• Switzer B , Puzanov I , Skitzki JJ , Hamad L , Ernstoff MS . Managing Metastatic Melanoma in 2022: A Clinical Review. JCO oncology practice 18(5), 335–351 (2022).
   PubMedGoogle Scholar
• Guo W , Wang H , Li C . Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 6(1), 424 (2021).
   PubMed Web of Science ®Google Scholar
• Lazaroff J , Bolotin D . Targeted Therapy and Immunotherapy in Melanoma. Dermatol. Clin. 41(1), 65–77 (2023).
   PubMed Web of Science ®Google Scholar
• Namikawa K , Yamazaki N . Targeted Therapy and Immunotherapy for Melanoma in Japan. Curr. Treat. Options Oncol. 20(1), 7 (2019).
   PubMed Web of Science ®Google Scholar
• Haas L , Elewaut A , Gerard CL et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature cancer 2(7), 693–708 (2021).
   PubMedGoogle Scholar
• Thornton J , Chhabra G , Singh CK , Guzmán-Pérez G , Shirley CA , Ahmad N . Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. Front. Oncol. 12, 880876 (2022).
   PubMed Web of Science ®Google Scholar
• Wagstaff W , Mwamba RN , Grullon K et al. Melanoma: molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance. Genes & diseases 9(6), 1608–1623 (2022).
   PubMed Web of Science ®Google Scholar
• Min HY , Lee HY . Oncogene-Driven Metabolic Alterations in Cancer. Biomol. Ther. (Seoul) 26(1), 45–56 (2018).
   PubMed Web of Science ®Google Scholar
• Iyamu EW . The redox state of the glutathione/glutathione disulfide couple mediates intracellular arginase activation in HCT-116 colon cancer cells. Dig. Dis. Sci. 55(9), 2520–2528 (2010).
   PubMed Web of Science ®Google Scholar
• Mitin T , Hunt D , Shipley WU et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 14(9), 863–872 (2013).
   PubMed Web of Science ®Google Scholar
• Sideris S , Aoun F , Zanaty M et al. Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol 4(6), 1063–1067 (2016).
   PubMedGoogle Scholar
• Jyotsana N , Ta KT , Delgiorno KE . The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer. Front. Oncol. 12, 858462 (2022).
   PubMed Web of Science ®Google Scholar
• Mbah NE , Lyssiotis CA . Metabolic regulation of ferroptosis in the tumor microenvironment. J. Biol. Chem. 298(3), 101617 (2022).
   PubMed Web of Science ®Google Scholar
• Koppula P , Zhuang L , Gan B . Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12(8), 599–620 (2021).
   PubMed Web of Science ®Google Scholar
• Huang AC , Zappasodi R . A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat. Immunol. 23(5), 660–670 (2022).
   PubMed Web of Science ®Google Scholar
• Carlino MS , Larkin J , Long GV . Immune checkpoint inhibitors in melanoma. Lancet 398(10304), 1002–1014 (2021).
   PubMed Web of Science ®Google Scholar
• Lozano AX , Chaudhuri AA , Nene A et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat. Med. 28(2), 353–362 (2022).
   PubMed Web of Science ®Google Scholar
• Hegde PS , Chen DS . Top 10 Challenges in Cancer Immunotherapy. Immunity 52(1), 17–35 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang Y , Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 17(8), 807–821 (2020).
   PubMed Web of Science ®Google Scholar
• Magrì A , Germano G , Lorenzato A et al. High-dose vitamin C enhances cancer immunotherapy. Sci. Transl. Med. 12(532), (2020).
   PubMed Web of Science ®Google Scholar
• Galassi C , Musella M , Manduca N , Maccafeo E , Sistigu A . The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. Cells 10(9), (2021).
   PubMed Web of Science ®Google Scholar
• Ubellacker JM , Tasdogan A , Ramesh V et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585(7823), 113–118 (2020).
   PubMed Web of Science ®Google Scholar
• Marzagalli M , Ebelt ND , Manuel ER . Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. Semin. Cancer Biol. 59, 236–250 (2019).
   PubMed Web of Science ®Google Scholar
• Alrabadi NN , Abushukair HM , Ababneh OE et al. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Clin. Transl. Oncol. 23(9), 1885–1904 (2021).
   PubMed Web of Science ®Google Scholar
• Robert C , Ribas A , Schachter J et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 20(9), 1239–1251 (2019).
   PubMed Web of Science ®Google Scholar
• Hodi FS , Chiarion-Sileni V , Gonzalez R et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 19(11), 1480–1492 (2018).
   PubMed Web of Science ®Google Scholar
• Liu Q , Nie R , Li M et al. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma. Comput. Struct. Biotechnol. J. 19, 4472–4485 (2021).
   PubMed Web of Science ®Google Scholar
• Tang R , Xu J , Zhang B et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J. Hematol. Oncol. 13(1), 110 (2020).
   PubMed Web of Science ®Google Scholar